ICER issues final report for hATTR therapies with recommendations

ICER released its final evidence report on treatments for hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) recommending that insurers and payers develop prior authorization criteria for Onpattro patisiran and Tegsedi inotersen, and that manufacturers bring prices down to a level that aligns with clinical value. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) markets Onpattro. Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) are partnered on Tegsedi.

Alnylam launched Onpattro in August with an annual list price of $450,000 and a net price of $345,000. The therapy is approved in the U.S. to treat polyneuropathy caused by hATTR (hATTR) in adults. FDA approved Tegsedi earlier this month for the same indication, and Akcea said the therapy will have a maximum annual price of $450,000. Both companies are considering outcomes-based contracts for the therapies (see "FDA Approves Hereditary Amyloidosis Drug from Akcea, Ionis")...